Abstract:Abstract Background: Tumor influx of CD11b-expressing myeloid-derived suppressor cells (MDSCs) and M2 tumor-associated macrophages (TAMs) creates an immunosuppressive tumor microenvironment associated with resistance to anti-PD-1 antibody therapy. GB1275 is a novel, first-in-class, CD11b modulator that, in vivo, reduced MDSCs and TAMs at the tumor site, repolarized M2 immunosuppressive TAMs to an M1 phenotype, and increased tumor infiltration of activated CD8+ T cells. In combination with an anti-PD-1 antibody or chemotherapy, these immunomodulatory effects translated into potent anti-tumor effects and prolonged survival in orthotopic PDAC models. We hypothesize that GB1275-based therapy can alleviate myeloid cell-mediated immunosuppression and improve cancer treatment outcomes. Methods: This is an open-label, first-in-human study comprising phase 1 dose escalation of GB1275 monotherapy (Regimen A) and GB1275 plus pembrolizumab (Regimen B) in patients with previously treated, locally advanced or metastatic PDA, esophageal, gastric/GEJ, triple negative breast, castration-resistant prostate, or microsatellite-stable colorectal cancer (MSS CRC), and GB1275 plus nab-paclitaxel and gemcitabine (Nab-P+Gem) (Regimen C) in mPDAC. This is followed by phase 2 expansion in three disease cohorts: 1) newly diagnosed stage IV mPDAC (GB1275+Nab-P+Gem), 2) MSS CRC (GB1275+pembrolizumab), and 3) PD-L1+ gastric/GEJ cancer (GB1275+pembrolizumab). Patients are enrolled in Regimen A initially, with Regimen B commencing after completion of the first few cohorts of Regimen A. Regimen C will initiate when Regimen A is completed. Eligible patients are ≥18 years of age, with histologically confirmed locally advanced/metastatic tumor specified and ECOG 0-1 PS; prior immunotherapy is permissible during Regimen A and B dose escalation, but not Regimen C or during the expansion phase. Patients are excluded for untreated or symptomatic CNS metastasis, prior myeloid targeting treatment or other prohibited medications, or a history of clinically significant cardiovascular disease. Patients with active autoimmune disease requiring systemic therapy will be excluded from Regimen B and from expansion cohorts 2 and 3. Primary objectives for phase 1 are to determine the maximum tolerated dose/recommended phase dose and pharmacokinetic profile of GB1275 alone and combination with pembrolizumab, and safety in combination with Nab-P+Gem, and for phase 2, to assess efficacy.Statistical Considerations: A 3+3 design is used for the dose escalation phase and Simon's 2-stage design for the expansion phase. Adverse events are graded per CTCAE v5.0, responses per RECIST v1.1. This study is open for recruitment (NCT04060342). Citation Format: Andrea Wang-Gillam, Drew W. Rasco, Wungki Park, Eileen O'Reilly, Wells Messersmith, David G. DeNardo, Vineet Gupta, Lei Zhou, Anna Galkin, Debbie Slee, Laura L. Carter, David Nickle, Rebecca Tran, Jack Li, Beatrice Ferguson, Marya F. Chaney, Luisa Salter-Cid, Jakob Dupont, Johanna C. Bendell. A phase 1/2 study of GB1275, a first-in-class CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36) [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT247.

Phi-55: (nci#7427): A Phase I Study of Halichondrin B Analog (E7389) in Combination with Cisplatin (cddp) in Advanced Solid Tumors: A Ccc, Nci/Ctep-Sponsored Trial (grant U01 Ca 062505).

Phase 1/2 Study of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Advanced Solid Tumors: Interim Results from Dose-Escalation.

Abstract PS15-02: A Phase Ⅰb Study of D-0502 as Monotherapy for Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer: Results from the Dose-Expansion Stage

Phase I, Dose-Escalation Study of the Investigational Drug D07001-F4, an Oral Formulation of Gemcitabine HCl, in Patients (pts) with Advanced Solid Tumors or Lymphoma

Phase la study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR+/HER2-advanced breast cancer

A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours.

A Phase I Study of the Combination of Ro4929097 and Cediranib in Patients with Advanced Solid Tumours (PJC-004/NCI 8503).

Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.

Phase 1/2 first-in-human (FIH) study of CPI-0209, a novel small molecule inhibitor of enhancer of zeste homolog 2 (EZH2) in patients with advanced tumors.

Results of a Phase 1/2 Study of MHB088C: A Novel B7H3 Antibody-Drug Conjugate (ADC) Incorporating a Potent DNA Topoisomerase I Inhibitor in Recurrent or Metastatic Solid Tumors.

Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors

First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.

Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.

Abstract CT247: A phase 1/2 study of GB1275, a first-in-class CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36)

A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).

A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer

Phase II study evaluating the efficacy of PDS0301 in combination with hepatic artery infusion pump (HAIP) and systemic therapy for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma.

First-in-human Phase 1 Study of SPH4336, a Novel Cyclin-Dependent Kinase 4/6 Inhibitor, in Patients with Advanced Solid Tumors.

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients